Issue Date: November 17, 2008
Germany's Merck Starts Swiss Project
Merck KGaA's Merck Serono division is spending some $375 million to expand its production site in Corsier-sur-Vevey, Switzerland. The project will allow the company to boost output of Erbitux, the cancer-fighting monoclonal antibody that it markets with ImClone Systems. By 2010, Merck will add two production suites with a combined 120,000 L of bioreactor capacity.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society